Compare metabolites in 2 of these studies:
Study A:   Study B:  

List of Studies ( Metabolite:13,14-Dihydro-15-keto-PGF2alpha)

Study_idAnalysis_idStudy_titleSourceSpeciesDiseaseInstituteAnalysis Type
ST003049 AN005000 Plasma instead of serum avoids critical confounding of clinical metabolomics studies by platelets Blood Human University of Vienna LC-MS
ST002977 AN004889 Offline Two-dimensional Liquid Chromatography-Mass Spectrometry for Deep Annotation of the Fecal Metabolome following Fecal Microbiota Transplant Feces Human University of Michigan LC-MS
ST002455 AN004005 Organism-Wide Analysis of Sepsis Reveals Mechanisms of Systemic Inflammation Blood Mouse Sepsis University of Chicago LC-MS
ST002354 AN003843 Combination of TP-252 and Naproxen elicit tumor protective Eicosanoid changes. Blood Rat Cancer UConn Health LC-MS
ST002354 AN003843 Combination of TP-252 and Naproxen elicit tumor protective Eicosanoid changes. Colon Rat Cancer UConn Health LC-MS
ST002354 AN003845 Combination of TP-252 and Naproxen elicit tumor protective Eicosanoid changes. Blood Rat Cancer UConn Health LC-MS
ST002354 AN003845 Combination of TP-252 and Naproxen elicit tumor protective Eicosanoid changes. Colon Rat Cancer UConn Health LC-MS
ST001783 AN002894 Performance of Three Differential Metabolites at Different TSS within 20 days Blood Mouse Hebei medical university LC-MS
ST001215 AN002026 Effect of Mirabegron Treatment on serum lipidome Blood Human Joslin Diabetes Center LC-MS
ST001214 AN002025 Lipidommics in the serum of human subjects Blood Human Joslin Diabetes Center LC-MS
ST001213 AN002024 Serum lipidomic profile of cold-exposed Ucp1cre/12-LOX KO mice Blood Mouse Joslin Diabetes Center LC-MS
ST001207 AN002009 Lipidomics in the serum of cold exposed mice treated with 12-LOX inhibitor LOXBlock-1 Blood Mouse Joslin Diabetes Center LC-MS
ST001206 AN002008 Effects of cold exposure on serum lipidomic in mice Blood Mouse Joslin Diabetes Center LC-MS
ST000917 AN001497 Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 3:Urine Urine Human Fatty liver disease LIPID MAPS GC-MS/LC-MS
ST000916 AN001491 Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Plasma Blood Human Fatty liver disease LIPID MAPS GC-MS/LC-MS
ST000915 AN001485 Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Liver Liver Human Fatty liver disease LIPID MAPS GC-MS/LC-MS
ST000142 AN000225 H1299 13C-labeled Cell Study Lung Human Cancer University of Kentucky LC-MS
ST000047 AN000080 Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (CSF) Cerebrospinal fluid Human Alzheimers disease Mayo Clinic LC-MS
ST000046 AN000079 Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (plasma) Blood Human Alzheimers disease Mayo Clinic LC-MS
ST000004 AN000004 Lipidomics studies on NIDDK / NIST human plasma samples Blood Human LIPID MAPS LC-MS
  logo